Revenue (Tables)

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Net product revenue	$	6,979.8	$	5,870.9	$	13,218.0	$	13,003.8
Collaboration and other revenue(1)	1,332.3		617.1		2,054.1		1,294.2
Revenue	$	8,312.1	$	6,488.0	$	15,272.1	$	14,298.0

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $30.3 million and $55.4 million during the three and six months ended June 30, 2023, respectively, and $34.4 million and $87.6 million during the three and six months ended June 30, 2022, respectively.

The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended June 30, 2023 and 2022:


	Three Months Ended June 30,
	2023						2022
	U.S.		Outside U.S.		Total		U.S.		Outside U.S.		Total

Diabetes:
Trulicity®	$	1,371.3	$	441.2	$	1,812.5	$	1,430.1	$	481.7	$	1,911.9
Mounjaro®	915.7		64.0		979.7		12.6		3.4		16.0
Jardiance(1)	386.1		282.2		668.3		250.7		210.3		461.0
Baqsimi	606.2		7.7		613.9		21.8		7.2		29.0
Humalog® (2)	229.8		210.6		440.4		238.8		208.3		447.1
Humulin®	144.3		61.0		205.3		202.3		71.7		274.0
Basaglar® (3)	83.0		71.2		154.2		95.8		78.4		174.2
Other diabetes	45.0		91.6		136.6		40.1		85.0		125.0
Total diabetes	3,781.4		1,229.5		5,010.9		2,292.2		1,146.0		3,438.2

Oncology:
Verzenio®	588.6		338.2		926.8		384.3		204.2		588.5
Cyramza®	115.0		145.3		260.3		92.6		138.6		231.3
Erbitux®	145.5		17.0		162.5		125.1		15.7		140.8
Alimta®	17.9		43.1		60.9		171.7		56.1		227.7
Other oncology	68.0		192.4		260.5		45.3		135.2		180.4
Total oncology	935.0		736.0		1,671.0		819.0		549.8		1,368.7

Immunology:
Taltz®	472.3		231.6		703.9		411.6		194.7		606.2
Olumiant® (4)	50.8		168.1		218.9		10.4		175.8		186.2
Other immunology	—		5.7		5.7		—		4.0		4.0
Total immunology	523.1		405.4		928.5		422.0		374.5		796.5

Neuroscience:
Emgality®	118.8		50.5		169.3		108.6		48.9		157.5

Other neuroscience	42.1		175.8		217.9		36.2		196.3		232.4
Total neuroscience	160.9		226.3		387.2		144.8		245.2		389.9


Other:
Forteo®	97.4		50.6		148.0		78.5		60.0		138.5
Cialis®	9.2		106.4		115.6		10.8		136.2		147.0
COVID-19 antibodies(5)	—		—		—		129.1		—		129.1
Other	24.4		26.5		51.0		38.5		41.7		80.1
Total other	131.0		183.5		314.6		256.9		237.9		494.7
Revenue	$	5,531.4	$	2,780.7	$	8,312.1	$	3,934.8	$	2,553.3	$	6,488.0

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.

(2) Humalog revenue includes insulin lispro.

(3) Basaglar revenue includes Rezvoglar®.

(4) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.

(5) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.

The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the six months ended June 30, 2023 and 2022:


	Six Months Ended June 30,
	2023						2022
	U.S.		Outside U.S.		Total		U.S.		Outside U.S.		Total

Diabetes:
Trulicity	$	2,918.7	$	871.0	$	3,789.6	$	2,744.1	$	909.1	$	3,653.2
Mounjaro	1,452.2		96.0		1,548.2		12.6		3.4		16.0
Jardiance(1)	715.6		530.2		1,245.8		480.4		400.0		880.4
Humalog(2)	501.4		400.0		901.4		607.7		457.6		1,065.3
Baqsimi	629.3		16.1		645.4		44.3		13.9		58.2
Humulin	343.1		114.2		457.3		392.8		154.5		547.2
Basaglar(3)	218.4		145.2		363.5		215.1		150.6		365.7
Other diabetes	77.7		172.2		250.1		71.7		168.5		240.3
Total diabetes	6,856.4		2,344.9		9,201.3		4,568.7		2,257.6		6,826.3

Oncology:
Verzenio	1,049.6		628.0		1,677.7		685.7		372.1		1,057.9
Cyramza	215.6		281.4		497.0		171.8		289.7		461.5
Erbitux	264.2		28.1		292.4		234.7		28.7		263.4
Alimta	38.0		81.2		119.1		425.9		145.8		571.7
Other oncology	121.0		319.9		440.8		84.6		282.7		367.2
Total oncology	1,688.4		1,338.6		3,027.0		1,602.7		1,119.0		2,721.7

Immunology:
Taltz	784.5		446.3		1,230.8		718.8		375.5		1,094.3
Olumiant(4)	93.1		354.6		447.8		81.7		360.1		441.8
Other immunology	—		27.7		27.7		—		8.5		8.5
Total immunology	877.6		828.6		1,706.3		800.5		744.1		1,544.6

Neuroscience:
Emgality	227.5		96.1		323.6		216.9		89.8		306.7

Other neuroscience	77.9		346.2		424.1		81.2		399.7		481.0
Total neuroscience	305.4		442.3		747.7		298.1		489.5		787.7

Other:
Forteo	168.0		102.3		270.3		148.7		127.2		275.9
Cialis	16.8		199.1		215.9		17.7		347.0		364.7
COVID-19 antibodies(5)	—		—		—		1,584.3		14.7		1,598.9
Other	55.0		48.7		103.7		88.5		89.6		178.2
Total other	239.8		350.1		589.9		1,839.2		578.5		2,417.7
Revenue	$	9,967.6	$	5,304.6	$	15,272.1	$	9,109.4	$	5,188.7	$	14,298.0

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.

(2) Humalog revenue includes insulin lispro.

(3) Basaglar revenue includes Rezvoglar.

(4) Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.

The following table summarizes revenue by geographical area:


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Revenue(1):
U.S.	$	5,531.4	$	3,934.8	$	9,967.6	$	9,109.4
Europe	1,177.6		1,101.1		2,268.5		2,168.4
Japan	455.6		454.4		842.8		864.6
China	399.0		352.1		771.7		758.5
Other foreign countries	748.5		645.7		1,421.5		1,397.2
Revenue	$	8,312.1	$	6,488.0	$	15,272.1	$	14,298.0

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer or other party.

Schedule of amounts recorded for contract liabilities

The following table summarizes contract liability balances:


	June 30, 2023		December 31, 2022
Contract liabilities	$	211.1	$	219.2